Klygefa Alexion Pharmaceuticals Australasia Pty Ltd
Product name
Klygefa
Accepted date
May-2026
Active ingredients
gefurulimab
Summary of proposed indication
KLYGEFA (gefurulimab) is proposed as a treatment for adults with generalised myasthenia gravis that is associated with anti-acetylcholine receptor antibodies, proteins made by the immune system that mistakenly attack the connection between nerves and muscles. This results in widespread muscle weakness.
Application type
A (new medicine)
Publication date
May-2026